中国修复重建外科杂志

中国修复重建外科杂志

关节腔注射富血小板血浆对膝骨关节炎患者关节液及血浆中 IL-17 的影响

查看全文

目的 探讨关节腔注射富血小板血浆(platelet-rich plasma,PRP)治疗后,膝骨关节炎(osteoar-thritis,OA)患者血浆和关节滑液中 IL-17 水平变化。 方法 以 2015 年 1 月—2016 年 1 月接受关节腔 PRP 注射治疗(每周 1 次,连续 3 周)的 30 例膝关节 OA 患者作为研究对象(试验组),以 30 例自愿者正常膝关节作为对照(对照组)。两组研究对象性别、年龄、体质量指数比较,差异均无统计学意义(P>0.05)。试验组治疗前后采用膝关节学会评分系统(KSS)及疼痛视觉模拟评分(VAS)分别评价膝关节功能及疼痛程度。试验组患者注射 PRP 之前及第 3 次注射后 1、3、6 及 12 个月抽取肘前静脉血以及患侧关节滑液,采用 ELISA 法测量 IL-17 含量;对照组抽取肘前静脉血进行相应检测并比较。 结果 PRP 注射治疗过程中,试验组患者均未出现膝关节红肿、发热等局部感染及其他不适症状。患者均获随访,随访时间 12~15 个月,平均 13.5 个月。PRP 注射治疗后各时间点 VAS 评分均较术前显著降低,KSS 评分较术前显著增加,比较差异有统计学意义(P<0.05);治疗后各时间点间比较,差异均无统计学意义(P>0.05)。与对照组比较,试验组 PRP 治疗前后血浆 IL-17 含量均显著增高(P<0.05)。试验组治疗后各时间点血浆及关节滑液 IL-17 含量均较治疗前显著降低(P<0.05),治疗后各时间点间比较差异均无统计学意义(P>0.05)。 结论 关节腔注射 PRP 治疗可显著改善膝关节 OA 患者疼痛症状及关节功能,并在一定程度上降低患者体内 IL-17 水平,但未恢复至正常水平。

Objective To investigate the interleukin-17 (IL-17) levels changes in both synovial fluid and venous plasma of patients with primary knee osteoarthritis (OA) after intra-articular injection of platelet-rich plasma (PRP). Methods Between January 2015 and January 2016, 30 patients with primary knee OA were treated by intra-articular injection of PRP once a week for 3 weeks (trial group). Thirty healthy individuals were recruited into the study as control. There was no significant difference in gender, age, and body mass index between 2 groups (P>0.05). Visual analogue scale (VAS) score and Knee Society Score (KSS) were used to evaluate pain level and function of the knee for patients with OA. The IL-17 levels in both venous plasma and synovial fluid were measured before injection and at 1, 3, 6, and 12 months after injection in trial group and the IL-17 levels in venous plasma were measured in control group. The levels were determined using ELISA method. Results There was no knee joint swelling, fever, local infection, or other uncomfortable symptoms for all patients in process of PRP injection. All patients were followed up 13.5 months on average (range, 12-15 months). In trial group, the VAS scores at different time points after injection were significantly lower than that before injection (P<0.05). And the KSS scores at different time points after injection were significantly higher than that before injection (P<0.05). There was no significant difference in VAS and KSS scores between different time points after injection (P>0.05). The IL-17 levels in venous plasma before and after injection in trial group were significantly higher than that in control group (P<0.05). The IL-17 levels in venous plasma at each time point after injection were significantly lower than that before injection (P<0.05). There was no significant difference in IL-17 levels in both venous plasma and synovial fluid between different time points after injection (P>0.05). Conclusion Intra-articular injection of PRP can significantly release the pain symptoms, improve joint function, and reduce IL-17 levels in both synovial fluid and venous plasma of the patients with knee OA, but IL-17 levels can not reduce to normal level.

关键词: 富血小板血浆; IL-17; 骨关节炎; 膝关节

Key words: Platelet-rich plasma; interleukin-17; osteoarthritis; knee

引用本文: 张海森, 白玉明, 刘畅, 靳胜利, 苏珂, 刘颖, 吕志昌. 关节腔注射富血小板血浆对膝骨关节炎患者关节液及血浆中 IL-17 的影响. 中国修复重建外科杂志, 2017, 31(8): 918-921. doi: 10.7507/1002-1892.201704013 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Cooper BG, Stewart RC, Burstein D, et al. A tissue-penetrating double network restores the mechanical properties of degenerated articular cartilage. Angew Chem Int Ed Engl, 2016, 55(13): 4226-4230.
2. Honsawek S, Deepaisarnsakul B, Tanavalee A, et al. Association of the IL-6 -174G/C gene polymorphism with knee osteoarthritis in a Thai population. Genet Mol Res, 2011, 10(3): 1674-1680.
3. Hulin-Curtis SL, Bidwell JL, Perry MJ. Evaluation of IL18 and IL18R1 polymorphisms: genetic susceptibility to knee osteoarthritis. Int J Immunogenet, 2012, 39(2): 106-109.
4. 张海森, 白玉明, 靳胜利, 等. 白细胞介素-17 基因多态性与骨关节炎易感性之间的相关性研究. 中华骨科杂志, 2016, 36(22): 1450-1455.
5. 张海森, 白玉明, 刘畅, 等. 血清及滑液白介素-17 水平与膝骨关节炎退变及膝痛程度的相关性研究. 中国医药导报, 2016, 13(33): 84-87.
6. Kan J, Mishima S, Kashiwakura J, et al. Interleukin-17A expression in human synovial mast cells in rheumatoid arthritis and osteoarthritis. Allergol Int, 2016, 65 Suppl: S11-S16.
7. Sadeghi-Ataabadi M, Mostafavi-Pour Z, Vojdani Z, et al. Fabrication and characterization of platelet-rich plasma scaffolds for tissue engineering applications. Mater Sci Eng C Mater Biol Appl, 2017, 71: 372-380.
8. Duymus TM, Mutlu S, Dernek B, et al. Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or ozone options. Knee Surg Sports Traumatol Arthrosc, 2017, 25(2): 485-492.
9. Shen L, Yuan T, Chen S, et al. The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. J Orthop Surg Res, 2017, 12(1): 16.
10. Montañezheredia E, Irízar S, Huertas PJ, et al. Intra-articular injections of platelet-rich plasma versus hyaluronic acid in the treatment of osteoarthritic knee pain: A randomized clinical trial in the context of the spanish national health care system. Int J Mol Sci, 2016, 17(7): 1064.
11. Repetto I, Biti B, Cerruti P, et al. Conservative Treatment of Ankle Osteoarthritis: Can Platelet-Rich Plasma Effectively Postpone Surgery? J Foot Ankle Surg, 2017, 56(2): 362-365.
12. van Oudenaarde K, Jobke B, Oostveen AC, et al. Predictive value of MRI features for development of radiographic osteoarthritis in a cohort of participants with pre-radiographic knee osteoarthritis-the CHECK study. Rheumatology (Oxford), 2017, 56(1): 113-120.
13. Altman RD. Criteria for the classification of osteoarthritis of the knee and hip. Scand J Rheumatol Suppl, 1987, 65: 31-39.
14. Silva AL, Demange MK, Gobbi RG, et al. Translation and Validation of the Knee Society Score-KSS for Brazilian Portuguese. Acta Ortop Bras, 2012, 20(1): 25-30.
15. Karabis A, Nikolakopoulos S, Pandhi S, et al. High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications. Arthritis Res Ther, 2016, 18(1): 1-7.
16. Bondeson J, Wainwright SD, Lauder S, et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther, 2006, 8(6): R187.
17. Wu X, Kondragunta V, Kornman KS, et al. IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort. Osteoarthritis Cartilage, 2013, 21(7): 930-938.
18. Chen L, Li DQ, Zhong J, et al. IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis. Osteoarthritis Cartilage, 2011, 19(6): 711-718.
19. Wang K, Xu JH, Cai JY, et al. Serum levels of interleukin-17 and adiponectin are associated with infrapatellar fat pad volume and signal intensity alteration in patients with knee osteoarthritis. Arthritis Res Ther, 2016, 18(1): 193.
20. Deligne C, Casulli S, Pigenet A, et al. Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients. Osteoarthritis Cartilage, 2015, 23(11): 1843-1852.
21. Wang K, Xu J, Cai J, et al. Serum levels of resistin and interleukin-17 are associated with increased cartilage defects and bone marrow lesions in patients with knee osteoarthritis. Mod Rheumatol, 2017, 27(2): 339-344.
22. 翟文亮, 周亮, 刘晖, 等. 富血小板血浆与透明质酸钠治疗膝关节骨关节炎的临床观察. 中华关节外科杂志(电子版), 2017, 11 (1): 90-93.
23. 刘步云, 孙育良, 何本祥, 等. 关节腔注射富血小板血浆与玻璃酸钠治疗膝关节骨关节炎的疗效比较. 实用骨科杂志, 2017, 23 (1): 71-73.
24. 冯晓林, 牟奎, 王建春, 等. 富血小板血浆用于膝关节骨关节炎的临床研究. 中华实验外科杂志, 2016, 33 (12): 2792-2793.
25. 丁权威, 吕帅洁, 沈兴潮, 等. 富血小板血浆联合透明质酸钠关节内注射治疗膝骨关节炎的前瞻性随机对照研究. 上海医药, 2017, 38(5): 25-28, 40.